Treatment guidelines recommend lithium as a first-line option for relapse prevention and suicide prevention in bipolar I disorder. However, there is a disparity between research efficacy and clinical effectiveness, with only a third of patients having an excellent response to long-term treatment. Nowadays, lithium use is in decline, which is probably influenced by the predominance of sub-optimal responses, the need for blood monitoring, the perception that lithium is more toxic than other medications, and the often lengthy trials necessary to determine response. For every factor, there is scope to improve our knowledge of lithium, and room to move towards more effective, safe, and ultimately personalised prescription, which is the goal of the .

中文翻译：

---

锂：过去，现在和未来。

治疗指南建议将锂作为双相性I型疾病预防复发和自杀预防的一线选择。但是，研究功效和临床功效之间存在差异，只有三分之一的患者对长期治疗有良好的反应。如今，锂的使用量正在下降，这可能受到次优反应的普遍性，对血液监测的需求，对锂比其他药物毒性更大的认识以及确定反应所需的通常冗长的试验的影响。对于每个因素，都有提高我们对锂知识的空间，还有朝着更有效，安全和最终个性化的处方发展的空间，这是该产品的目标。